Advances in thymoma imaging

Journal of Thoracic Imaging

Volumn 28, Issue 2, 2013, Pages 69-83

  Marom, Edith M ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Computed tomography; Magnetic resonance imaging; Positron emission tomography; Staging; Thymoma

Indexed keywords

ACETIC ACID C 11; ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18; GALLIUM CITRATE GA 67; METHIONINE C 11; PENTETREOTIDE IN 111; SOMATOMEDIN C RECEPTOR; TETRAXETAN; THALLIUM CHLORIDE TL 201;

ADJUVANT THERAPY; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; DIFFERENTIAL DIAGNOSIS; FOLLOW UP; GERM CELL TUMOR; HUMAN; LUNG SMALL CELL CANCER; LYMPHOMA; MEDIASTINUM METASTASIS; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PROGRESSION FREE SURVIVAL; REVIEW; THORAX RADIOGRAPHY; THYMOMA; THYMUS CANCER; TUMOR DIAGNOSIS; TUMOR RECURRENCE; TUMOR VOLUME; UNITED STATES;

DIAGNOSIS, DIFFERENTIAL; DIAGNOSTIC IMAGING; HUMANS; MAGNETIC RESONANCE IMAGING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOGRAPHIC IMAGE ENHANCEMENT; THYMOMA; THYMUS HYPERPLASIA; THYMUS NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84874637612     PISSN: 08835993     EISSN: 15360237     Source Type: Journal    
DOI: 10.1097/RTI.0b013e31828609a0     Document Type: Review

References (76)

1. Duwe BV, Sterman DH, Musani AI. Tumors of the mediastinum. Chest. 2005;128:2893-2909.
2. Engels EA. Epidemiology of thymoma and associated malignancies. J Thorac Oncol. 2010;5:S260-S265.
3. Travis WD, Brambilla E, Muller-Hermelik HK, et al. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon: IARC Press; 2004.
4. Osserman KE, Genkins G. Studies in myasthenia gravis: review of a twenty-year experience in over 1200 patients. Mt Sinai J Med. 1971;38:497-537.
5. Cameron RB, Loehrer PJ Sr, Thomas CR Jr. Neoplasms of the mediastinum. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Principles and Practice of Oncology. 7th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2005:845-858.
6. Levy Y, Afek A, Sherer Y, et al. Malignant thymoma associated with autoimmune diseases: a retrospective study and review of the literature. Semin Arthritis Rheum. 1998;28:73-79.
7. Henschke CI, Lee IJ, Wu N, et al. CT screening for lung cancer: prevalence and incidence of mediastinal masses. Radiology. 2006;239:586-590.
8. Regnard JF, Magdeleinat P, Dromer C, et al. Prognostic factors and long-term results after thymoma resection: a series of 307 patients. J Thorac Cardiovasc Surg. 1996;112:376-384.
9. Kondo K, Yoshizawa K, Tsuyuguchi M, et al. WHO histologic classification is a prognostic indicator in thymoma. Ann Thorac Surg. 2004;77:1183-1188.
10. Suster S, Moran CA. Histologic classification of thymoma: the World Health Organization and beyond. Hematol Oncol Clin North Am. 2008;22:381-392.
11. Rieker RJ, Hoegel J, Morresi-Hauf A, et al. Histologic classification of thymic epithelial tumors: comparison of established classification schemes. Int J Cancer. 2002;98:900-906.
12. Moran CA, Weissferdt A, Kalhor N, et al. Thymomas I: a clinicopathologic correlation of 250 cases with emphasis on the World Health Organization schema. Am J Clin Pathol. 2012;137:444-450.
13. Chalabreysse L, Roy P, Cordier JF, et al. Correlation of the WHO schema for the classification of thymic epithelial neoplasms with prognosis: a retrospective study of 90 tumors. Am J Surg Pathol. 2002;26:1605-1611.
14. Chen G, Marx A, Wen-Hu C, et al. New WHO histologic classification predicts prognosis of thymic epithelial tumors: a clinicopathologic study of 200 thymoma cases from China. Cancer. 2002;95:420-429.
15. Suster S, Moran CA. Thymoma, atypical thymoma, and thymic carcinoma. A novel conceptual approach to the classification of thymic epithelial neoplasms. Am J Clin Pathol. 1999;111:826-833.
16. Casey EM, Kiel PJ, Loehrer PJ Sr. Clinical management of thymoma patients. Hematol Oncol Clin North Am. 2008;22: 457-473.
17. Koga KMY, Noguchi M, Mukai K, et al. A review of 79 thymomas: modification of staging system and reappraisal of coventional division into invasive and non-invasive thymoma. Pathol Int. 1994;44:359-367.
18. Masaoka AMY, Nakahara K, Tanioka T. Follow-up study of thymomas with special reference to their clinical stages. Cancer. 1981;2485-2492.
19. Moran CA, Walsh G, Suster S, et al. Thymomas II: a clinicopathologic correlation of 250 cases with a proposed staging system with emphasis on pathologic assessment. Am J Clin Pathol. 2012;137:451-461.
20. Gamondes JP, Balawi A, Greenland T, et al. Seventeen years of surgical treatment of thymoma: factors influencing survival. Eur J Cardiothorac Surg. 1991;5:124-131.
21. Yamakawa Y, Masaoka A, Hashimoto T, et al. A tentative tumor-node-metastasis classification of thymoma. Cancer. 1991;68:1984-1987.
22. Huang J, Detterbeck FC, Wang Z, et al. Standard outcome measures for thymic malignancies. J Thorac Oncol. 2011; 6:S1691-S1697.
23. Girard N, Mornex F, Van Houtte P, et al. Thymoma: a focus on current therapeutic management. J Thorac Oncol. 2009;4: 119-126.
24. Falkson CB, Bezjak A, Darling G, et al. The management of thymoma: a systematic review and practice guideline. J Thorac Oncol. 2009;4:911-919.
25. Kim ES, Putnam JB, Komaki R, et al. Phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy, and consolidation chemotherapy for unresectable malignant thymomas: final report. Lung Cancer. 2004;44:369-379.
26. Rea F, Sartori F, Loy M, et al. Chemotherapy and operation for invasive thymoma. J Thorac Cardiovasc Surg. 1993;106:543-549.
27. Venuta F, Rendina EA, Longo F, et al. Long-term outcome after multimodality treatment for stage III thymic tumors. Ann Thorac Surg. 2003;76:1866-1872; discussion 1872.
28. Venuta F, Rendina EA, Pescarmona EO, et al. Multimodality treatment of thymoma: a prospective study. Ann Thorac Surg. 1997;64:1585-1591; discussion 1591-1582.
29. Tomiyama N, Honda O, Tsubamoto M, et al. Anterior mediastinal tumors: diagnostic accuracy of CT and MRI. Eur J Radiol. 2009;69:280-288.
30. Restrepo CS, Pandit M, Rojas IC, et al. Imaging findings of expansile lesions of the thymus. Curr Probl Diagn Radiol. 2005;34:22-34.
31. Rosado-de-Christenson ML, Galobardes J, Moran CA. Thymoma: radiologic-pathologic correlation. Radiographics. 1992;12:151-168.
32. Brown LR, Muhm JR, Gray JE. Radiographic detection of thymoma. Am J Roentgenol. 1980;134:1181-1188.
33. Jeong YJ, Lee KS, Kim J, et al. Does CT of thymic epithelial tumors enable us to differentiate histologic subtypes and predict prognosis? Am J Roentgenol. 2004;183:283-289.
34. Chen JL, Weisbrod GL, Herman SJ. Computed tomography and pathologic correlations of thymic lesions. J Thorac Imaging. 1988;3:61-65.
35. Fon GT, Bein ME, Mancuso AA, et al. Computed tomography of the anterior mediastinum in myasthenia gravis. A radiologic-pathologic correlative study. Radiology. 1982;142: 135-141.
36. Tomiyama N, Johkoh T, Mihara N, et al. Using the World Health Organization Classification of thymic epithelial neoplasms to describe CT findings. Am J Roentgenol. 2002; 179:881-886.
37. Sadohara J, Fujimoto K, Muller NL, et al. Thymic epithelial tumors: comparison of CT and MR imaging findings of low-risk thymomas, high-risk thymomas, and thymic carcinomas. Eur J Radiol. 2006;60:70-79.
38. Yakushiji S, Tateishi U, Nagai S, et al. Computed tomographic findings and prognosis in thymic epithelial tumor patients. J Comput Assist Tomogr. 2008;32:799-805.
39. Marom EM, Milito MA, Moran CA, et al. Computed tomography findings predicting invasiveness of thymoma. J Thorac Oncol. 2011;6:1274-1281.
40. Priola AM, Priola SM, Di Franco M, et al. Computed tomography and thymoma: distinctive findings in invasive and noninvasive thymoma and predictive features of recurrence. Radiol Med. 2010;115:1-21.
41. Tomiyama N, Muller NL, Ellis SJ, et al. Invasive and noninvasive thymoma: distinctive CT features. J Comput Assist Tomogr. 2001;25:388-393.
42. Qu YJ, Liu GB, Shi HS, et al. Preoperative CT findings of thymoma are correlated with postoperative masaoka clinical stage. Acad Radiol. 2012;20:66-70.
43. Maher MM, Shepard JA. Imaging of thymoma. Semin Thorac Cardiovasc Surg. 2005;17:12-19.
44. Reubi JC, Waser B, Horisberger U, et al. In vitro autoradiographic and in vivo scintigraphic localization of somatostatin receptors in human lymphatic tissue. Blood. 1993;82:2143-2151.
45. Sakai S, Murayama S, Soeda H, et al. Differential diagnosis between thymoma and non-thymoma by dynamic MR imaging. Acta Radiol. 2002;43:262-268.
46. Han HJ, Park SJ, Min KH, et al. Whole-body magnetic resonance imaging for staging metastatic thymic carcinoma. Am J Respir Crit Care Med. 2011;183:1573-1574.
47. Krenning EP, Kwekkeboom DJ, Bakker WH, et al. Somatos-tatin receptor scintigraphy with [111In-DTPA-D-Phe1]-and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med. 1993;20:716-731.
48. Fletcher BD. Thymic concentration of radiolabeled octreotide. J Nucl Med. 1999;40:1967.
49. Lastoria S, Vergara E, Palmieri G, et al. In vivo detection of malignant thymic masses by indium-111-DTPA-D-Phe1-octreotide scintigraphy. J Nucl Med. 1998;39:634-639.
50. Rosati MS, Longo F, Messina CG, et al. Targeting the therapy: octreotide in thymoma relapse. J Clin Oncol. 2005;23:2064.
51. Loehrer PJ Sr, Wang W, Johnson DH, et al. Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: an Eastern Cooperative Oncology Group Phase II Trial. J Clin Oncol. 2004;22:293-299.
52. Buchmann I, Henze M, Engelbrecht S, et al. Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2007;34:1617-1626.
53. Miederer M, Seidl S, Buck A, et al. Correlation of immunohistopathological expression of somatostatin receptor 2 with standardised uptake values in 68Ga-DOTATOC PET/CT. Eur J Nucl Med Mol Imaging. 2009;36:48-52.
54. Lastoria S, Palmieri G, Muto P, et al. Functional imaging of thymic disorders. Ann Med. 1999;31(suppl 2):63-69.
55. Kaira K, Sunaga N, Ishizuka T, et al. The role of [(1)(8)F] fluorodeoxyglucose positron emission tomography in thymic epithelial tumors. Cancer Imaging. 2011;11:195-201.
56. Igai H, Matsuura N, Tarumi S, et al. Usefulness of [18F]fluoro-2-deoxy-D- glucose positron emission tomography for predicting the World Health Organization malignancy grade of thymic epithelial tumors. Eur J Cardiothorac Surg. 2011;40:143-145.
57. Kaira K, Endo M, Abe M, et al. Biologic correlation of 2-[18F]-fluoro-2-deoxy-D-glucose uptake on positron emission tomography in thymic epithelial tumors. J Clin Oncol. 2010;28:3746-3753.
58. Kumar A, Regmi SK, Dutta R, et al. Characterization of thymic masses using (18)F-FDG PET-CT. Ann Nucl Med. 2009;23: 569-577.
59. Sasaki M, Kuwabara Y, Ichiya Y, et al. Differential diagnosis of thymic tumors using a combination of 11C-methionine PET and FDG PET. J Nucl Med. 1999;40:1595-1601.
60. Shibata H, Nomori H, Uno K, et al. 18F-fluorodeoxyglucose and 11C-acetate positron emission tomography are useful modalities for diagnosing the histologic type of thymoma. Cancer. 2009;115:2531-2538.
61. Sung YM, Lee KS, Kim BT, et al. 18F-FDG PET/CT of thymic epithelial tumors: usefulness for distinguishing and staging tumor subgroups. J Nucl Med. 2006;47:1628-1634.
62. Terzi A, Bertolaccini L, Rizzardi G, et al. Usefulness of 18-F FDG PET/CT in the pre-treatment evaluation of thymic epithelial neoplasms. Lung Cancer. 2011;74:239-243.
63. Benveniste MFK, Moran CA, Mawlawi O, et al. FDG PET-CT aids in the preoperative assessment of patients with newly diagnosed thymic epithelial malignancies. J Thorac Oncol. (In press).
64. Fukumoto K, Taniguchi T, Ishikawa Y, et al. The utility of [18F]-fluorodeoxyglucose positron emission tomography-computed tomography in thymic epithelial tumours. Eur J Cardiothorac Surg. 2012;42:e152-e156.
65. Wahl RL, Jacene H, Kasamon Y, et al. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50(suppl 1):122S-150S.
66. Girard N, Teruya-Feldstein J, Payabyab EC, et al. Insulin-like growth factor-1 receptor expression in thymic malignancies. J Thorac Oncol. 2010;5:1439-1446.
67. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-247.
68. Byrne MJ, Nowak AK. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol. 2004;15:257-260.
69. Verley JM, Hollmann KH. Thymoma. A comparative study of clinical stages, histologic features, and survival in 200 cases. Cancer. 1985;55:1074-1086.
70. Regnard JF, Zinzindohoue F, Magdeleinat P, et al. Results of re-resection for recurrent thymomas. Ann Thorac Surg. 1997;64:1593-1598.
71. Strobel P, Bauer A, Puppe B, et al. Tumor recurrence and survival in patients treated for thymomas and thymic squamous cell carcinomas: a retrospective analysis. J Clin Oncol. 2004;22:1501-1509.
72. Inaoka T, Takahashi K, Mineta M, et al. Thymic hyperplasia and thymus gland tumors: differentiation with chemical shift MR imaging. Radiology. 2007;243:869-876.
73. Takahashi K, Inaoka T, Murakami N, et al. Characterization of the normal and hyperplastic thymus on chemical-shift MR imaging. Am J Roentgenol. 2003;180:1265-1269.
74. Ackman JB, Mino-Kenudson M, Morse CR. Nonsuppress-ing normal thymus on chemical shift magnetic resonance imaging in a young woman. J Thorac Imaging. 2012;27: W196-W198.
75. Jerushalmi J, Frenkel A, Bar-Shalom R, et al. Physiologic thymic uptake of 18F-FDG in children and young adults: a PET/CT evaluation of incidence, patterns, and relationship to treatment. J Nucl Med. 2009;50:849-853.
76. Luzzi L, Campione A, Gorla A, et al. Role of fluorine-flurodeoxyglucose positron emission tomography/computed tomography in preoperative assessment of anterior mediastinal masses. Eur J Cardiothorac Surg. 2009;36:475-479.